Trending NewsTrending NewsNASDAQ:LEGN Legend Biotech (LEGN) Stock Price, News & Analysis $15.25 -0.85 (-5.28%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$15.46 +0.22 (+1.41%) As of 11/20/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Legend Biotech Stock (NASDAQ:LEGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Legend Biotech alerts:Sign Up Key Stats Today's Range$15.15▼$16.1350-Day Range$15.25▼$24.2952-Week Range$15.15▼$37.50Volume3.42 million shsAverage Volume2.70 million shsMarket Capitalization$2.96 billionP/E RatioN/ADividend YieldN/APrice Target$48.64Consensus RatingModerate Buy Company Overview Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization. Legend’s pipeline includes additional investigational cell therapies for cancer. Through its collaboration and product development efforts, the company is working to bring its therapies to patients in multiple markets.AI Generated. May Contain Errors. Read More Legend Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreLEGN MarketRank™: 4.123639408315 of 5 starsLegend Biotech scored higher than 82% of companies evaluated by MarketBeat, and ranked 291st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingLegend Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 9 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialLegend Biotech has a consensus price target of $48.64, representing about 219.0% upside from its current price of $15.25.Amount of Analyst CoverageLegend Biotech has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Legend Biotech's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth638.46% Earnings GrowthEarnings for Legend Biotech are expected to grow by 638.46% in the coming year, from $0.13 to $0.96 per share.Price to Book Value per Share RatioLegend Biotech has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.14% of the float of Legend Biotech has been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 6.29.Change versus previous monthShort interest in Legend Biotech has recently decreased by 14.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLegend Biotech does not currently pay a dividend.Dividend GrowthLegend Biotech does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.20 News SentimentLegend Biotech has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Legend Biotech this week, compared to 5 articles on an average week.Search Interest5 people have searched for LEGN on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Legend Biotech insiders have sold 89.06% more of their company's stock than they have bought. Specifically, they have bought $163,200.00 in company stock and sold $308,550.00 in company stock.Percentage Held by Insiders0.02% of the stock of Legend Biotech is held by insiders.Percentage Held by Institutions70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Legend Biotech's insider trading history. Receive LEGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LEGN Stock News HeadlinesLegend Biotech (NASDAQ:LEGN) CEO Ingrid Zhang Buys 20,000 Shares of Company StockNovember 21 at 7:37 AM | insidertrades.comHC Wainwright Lowers Earnings Estimates for Legend BiotechNovember 21 at 2:28 AM | americanbankingnews.comWhoops! I wasn’t supposed to share this with you yetTraders have paid as much as $500 for technology like this. Thomas Wood of Base Camp Trading is offering his proprietary Snapback Indicator for just $7. There is no subscription and no recurring charge, and it's yours for life. The indicator is designed to help identify potential market turning points, showing when it may be time to buy, sell, or go short.November 21 at 1:00 AM | Base Camp Trading (Ad)Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Stock Has Consensus Price Target of $50.85 According to BrokeragesNovember 20 at 3:30 AM | americanbankingnews.comIs Return To Profit Altering The Investment Case For Legend Biotech (LEGN)?November 19 at 9:23 AM | finance.yahoo.comLegend Biotech (NASDAQ:LEGN) Hits New 12-Month Low Following Analyst DowngradeNovember 18 at 1:42 AM | americanbankingnews.comLegend Biotech: The Market Is Missing The Bigger PictureNovember 17, 2026 | seekingalpha.comLegend Biotech Earnings Call Signals Strong CARVYKTI MomentumNovember 15, 2026 | theglobeandmail.comSee More Headlines LEGN Stock Analysis - Frequently Asked Questions How have LEGN shares performed this year? Legend Biotech's stock was trading at $21.74 at the beginning of the year. Since then, LEGN shares have decreased by 29.9% and is now trading at $15.25. How were Legend Biotech's earnings last quarter? Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) released its earnings results on Tuesday, November, 10th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.13. The firm's revenue was up 32.0% on a year-over-year basis. Read the conference call transcript. When did Legend Biotech IPO? Legend Biotech (LEGN) raised $350 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 18,425,000 shares at $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO. Who are Legend Biotech's major shareholders? Legend Biotech's top institutional investors include State Street Corp (0.84%), Soleus Capital Management L.P. (0.56%), Matthews International Capital Management LLC (0.47%) and IvyRock Asset Management HK Ltd (0.40%). Insiders that own company stock include Ingrid Zhang, Ying Huang and Carlos E Santos. View institutional ownership trends. How do I buy shares of Legend Biotech? Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Legend Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Legend Biotech investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Micron Technology (MU), Rocket Lab (RKLB), CRISPR Therapeutics (CRSP), AST SpaceMobile (ASTS) and Palantir Technologies (PLTR). Company Calendar Last Earnings11/10/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 LEGN's financial health is in the Red zone, according to TradeSmith. LEGN has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LEGN CIK1801198 Webwww.legendbiotech.com Phone732-317-5050FaxN/AEmployees2,965Year Founded2014Price Target and Rating Average Price Target for Legend Biotech$48.64 High Price Target$74.00 Low Price Target$20.00 Potential Upside/Downside+219.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$296.80 million Net Margins-0.02% Pretax Margin2.37% Return on Equity-0.03% Return on Assets-0.02% Debt Debt-to-Equity RatioN/A Current Ratio3.95 Quick Ratio3.82 Sales & Book Value Annual Sales$1.03 billion Price / Sales2.87 Cash FlowN/A Price / Cash FlowN/A Book Value$6.56 per share Price / Book2.32Miscellaneous Outstanding Shares193,970,000Free Float193,930,000Market Cap$2.96 billion OptionableOptionable Beta0.55 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:LEGN) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Corporation Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.